Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data: does adding immunotherapy before lung surgery improve outcomes?

NCT ID NCT07169708

Knowledge-focused Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews medical records of 100 adults in Taiwan with resectable non-small cell lung cancer who received nivolumab (an immunotherapy) combined with chemotherapy before surgery. Researchers want to see if this approach helps shrink tumors completely and delays cancer return, and whether it is safe. The study does not give any new treatment—it only looks at data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The cohort patients will be selected from the assigned medical centers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years and older 2. Patients who are diagnosed with pathologically confirmed, non-metastatic, resectable NSCLC 3. Patients who have received at least one cycle of neoadjuvant nivolumab combined with chemotherapy since the approval of the regimen in February 2023, and who have at least one imaging assessment of EFS and surgical status recorded. For patients who underwent surgery, at least one pathological report is required. 4. Patients who have been followed up for at least 12 months (from first dose of neoadjuvant therapy to last medical record date at study site), exceptional case as follows: * Patients who expired within 12 months of follow-up * Patients who experience disease progression or recurrence but continue to follow-up 5. Participants with histologically confirmed Stage II-III NSCLC (per the 8th International Association for the Study of Lung Cancer) who are considered resectable. Exclusion Criteria: 1. Patients with distant metastasis (M1 disease according to the eighth edition of the American Joint Committee on Cancer \[AJCC\] cancer staging manual) prior to neoadjuvant therapy 2. Patients with N3 disease per AJCC 8th edition 3. Patients with known EGFR mutations or ALK translocation 4. Patients who have received any prior systemic therapy for NSCLC 5. Patients with a history of previous cancers or other concurrent malignancies within 10 years before the first dose of nivolumab

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chang Gung Memorial Hospital Kaohsiung Branch

    RECRUITING

    Kaohsiung City, Taiwan

  • Chang Gung Memorial Hospital Linkou Branch

    RECRUITING

    Taoyuan, Taiwan

  • China Medical University Hospital

    RECRUITING

    Taichung, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    RECRUITING

    Kaohsiung City, Taiwan

  • Kaohsiung Veterns General Hospital

    RECRUITING

    Kaohsiung City, Taiwan

  • Mackay Memorial Hospital Taipei Branch

    RECRUITING

    Taipei, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, Taiwan

  • Taipei Veteran General Hospital

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.